Digilab Biovision to Sell GenWay's Seppro IgY Proteomics Technology | GenomeWeb
NEW YORK (GenomeWeb News) — Digilab BioVision today said it will offer GenWay Biotech’s Seppro IgY proteomics technology from its Hannover, Germany, facility.
 
Digilab said Seppro’s IgY technology selectively partitions the 12 most abundant proteins from human serum or plasma.
 
Digilab said its Peptidomics products and services increase the sensitivity and selectivity needed for drug-development proteomics.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.